[go: up one dir, main page]

WO2008089201A3 - Composés de pipéridine substituée hétérocycliques et leurs utilisations - Google Patents

Composés de pipéridine substituée hétérocycliques et leurs utilisations Download PDF

Info

Publication number
WO2008089201A3
WO2008089201A3 PCT/US2008/051096 US2008051096W WO2008089201A3 WO 2008089201 A3 WO2008089201 A3 WO 2008089201A3 US 2008051096 W US2008051096 W US 2008051096W WO 2008089201 A3 WO2008089201 A3 WO 2008089201A3
Authority
WO
WIPO (PCT)
Prior art keywords
heterocyclic
substituted piperidine
orl
ligands
effective amount
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
PCT/US2008/051096
Other languages
English (en)
Other versions
WO2008089201A2 (fr
Inventor
Yoshiyasu Baba
Kevin C Brown
R Richard Goehring
Naoki Tsuno
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Shionogi and Co Ltd
Purdue Pharma LP
Original Assignee
Shionogi and Co Ltd
Purdue Pharma LP
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority to CN200880002219.8A priority Critical patent/CN101595100B/zh
Priority to AU2008206317A priority patent/AU2008206317B2/en
Priority to NZ578078A priority patent/NZ578078A/en
Priority to KR1020127008578A priority patent/KR101370434B1/ko
Priority to KR1020097017069A priority patent/KR101227072B1/ko
Priority to AT08727696T priority patent/ATE482206T1/de
Priority to SI200830118T priority patent/SI2076506T1/sl
Priority to DK08727696.0T priority patent/DK2076506T3/da
Priority to HR20100691T priority patent/HRP20100691T1/hr
Priority to DE602008002690T priority patent/DE602008002690D1/de
Priority to JP2009546482A priority patent/JP5462633B2/ja
Priority to MX2009007644A priority patent/MX2009007644A/es
Priority to ES08727696T priority patent/ES2353448T3/es
Application filed by Shionogi and Co Ltd, Purdue Pharma LP filed Critical Shionogi and Co Ltd
Priority to CA2675419A priority patent/CA2675419C/fr
Priority to PL08727696T priority patent/PL2076506T3/pl
Priority to EP08727696A priority patent/EP2076506B1/fr
Publication of WO2008089201A2 publication Critical patent/WO2008089201A2/fr
Publication of WO2008089201A3 publication Critical patent/WO2008089201A3/fr
Priority to ZA2009/03742A priority patent/ZA200903742B/en
Priority to IL199741A priority patent/IL199741A0/en
Priority to US12/503,598 priority patent/US8110602B2/en
Anticipated expiration legal-status Critical
Priority to AU2011200692A priority patent/AU2011200692B2/en
Priority to US13/349,522 priority patent/US8637502B2/en
Ceased legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/498—Pyrazines or piperazines ortho- and peri-condensed with carbocyclic ring systems, e.g. quinoxaline, phenazine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/10—Laxatives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/12—Antidiarrhoeals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/14—Antitussive agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/02—Drugs for disorders of the urinary system of urine or of the urinary tract, e.g. urine acidifiers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/08—Antiepileptics; Anticonvulsants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/22—Anxiolytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A61P25/36—Opioid-abuse
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/12—Antidiuretics, e.g. drugs for diabetes insipidus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D451/00—Heterocyclic compounds containing 8-azabicyclo [3.2.1] octane, 9-azabicyclo [3.3.1] nonane, or 3-oxa-9-azatricyclo [3.3.1.0<2,4>] nonane ring systems, e.g. tropane or granatane alkaloids, scopolamine; Cyclic acetals thereof
    • C07D451/14—Heterocyclic compounds containing 8-azabicyclo [3.2.1] octane, 9-azabicyclo [3.3.1] nonane, or 3-oxa-9-azatricyclo [3.3.1.0<2,4>] nonane ring systems, e.g. tropane or granatane alkaloids, scopolamine; Cyclic acetals thereof containing 9-azabicyclo [3.3.1] nonane ring systems, e.g. granatane, 2-aza-adamantane; Cyclic acetals thereof
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/08—Bridged systems

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Public Health (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Biomedical Technology (AREA)
  • Diabetes (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Hematology (AREA)
  • Psychiatry (AREA)
  • Obesity (AREA)
  • Addiction (AREA)
  • Pain & Pain Management (AREA)
  • Urology & Nephrology (AREA)
  • Child & Adolescent Psychology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Emergency Medicine (AREA)
  • Hospice & Palliative Care (AREA)
  • Endocrinology (AREA)
  • Pulmonology (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Hydrogenated Pyridines (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)

Abstract

L'invention concerne des composés de pipéridine substituée hétérocycliques, des compositions renfermant une dose efficace d'un composé de pipéridine substituée hétérocyclique ainsi que des méthodes de traitement ou de prévention d'une affection, telle que la douleur, consistant à administrer, à un animal ayant besoin d'un tel traitement, une dose efficace d'un composé de pipéridine substituée hétérocyclique.
PCT/US2008/051096 2007-01-16 2008-01-15 Composés de pipéridine substituée hétérocycliques et leurs utilisations Ceased WO2008089201A2 (fr)

Priority Applications (21)

Application Number Priority Date Filing Date Title
ES08727696T ES2353448T3 (es) 2007-01-16 2008-01-15 Piperidinas heterocíclico-sustituidas como ligandos de orl-1.
NZ578078A NZ578078A (en) 2007-01-16 2008-01-15 Heterocyclic-substituted piperidine as orl-1 ligands
KR1020127008578A KR101370434B1 (ko) 2007-01-16 2008-01-15 Ｏｒｌ-1 리간드로서의 헤테로시클릭-치환 피페리딘
KR1020097017069A KR101227072B1 (ko) 2007-01-16 2008-01-15 Ｏｒｌ-1 리간드로서의 헤테로시클릭-치환 피페리딘
AT08727696T ATE482206T1 (de) 2007-01-16 2008-01-15 Heterozyklische substituierte piperidine als orl- 1-liganden
SI200830118T SI2076506T1 (sl) 2007-01-16 2008-01-15 Heterociklično substituirani piperidini kot ORL-1 ligandi
DK08727696.0T DK2076506T3 (da) 2007-01-16 2008-01-15 Heterocyklisk substituerede piperidiner som ORL-1-ligander
HR20100691T HRP20100691T1 (hr) 2007-01-16 2008-01-15 Heterociklicki-supstituirani piperidini kao orl-1 ligandi
AU2008206317A AU2008206317B2 (en) 2007-01-16 2008-01-15 Heterocyclic-Substituted Piperidine as ORL-1 ligands
JP2009546482A JP5462633B2 (ja) 2007-01-16 2008-01-15 複素環置換ピペリジン化合物とその使用
MX2009007644A MX2009007644A (es) 2007-01-16 2008-01-15 Compuestos de piperidina heterociclicos sustituidos y usos de los mismos.
CN200880002219.8A CN101595100B (zh) 2007-01-16 2008-01-15 作为orl-1配体的杂环取代的哌啶
CA2675419A CA2675419C (fr) 2007-01-16 2008-01-15 Composes de piperidine substituee heterocycliques et leurs utilisations
DE602008002690T DE602008002690D1 (de) 2007-01-16 2008-01-15 Heterozyklische substituierte piperidine als orl-1-liganden
PL08727696T PL2076506T3 (pl) 2007-01-16 2008-01-15 Heterocyklicznie podstawione piperydyny jako ligandy ORL-1
EP08727696A EP2076506B1 (fr) 2007-01-16 2008-01-15 Composes de piperidine substituee heterocycliques comme ligands de orl-1
ZA2009/03742A ZA200903742B (en) 2007-01-16 2009-06-08 Heterocyclic-substituted piperidine as orl-1 ligands
IL199741A IL199741A0 (en) 2007-01-16 2009-07-07 Heterocyclic-substituted piperidine as orl-1 ligands
US12/503,598 US8110602B2 (en) 2007-01-16 2009-07-15 Compounds comprising heterocyclic-substituted piperidine for treating pain
AU2011200692A AU2011200692B2 (en) 2007-01-16 2011-02-17 Heterocyclic-substituted piperidine as ORL-1 ligands
US13/349,522 US8637502B2 (en) 2007-01-16 2012-01-12 2,3,4,5-tetrahydro-benzo{B}{1,4}diazepine-comprising compounds of formula(III) for treating pain

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US88095507P 2007-01-16 2007-01-16
US60/880,955 2007-01-16
US93003507P 2007-05-11 2007-05-11
US60/930,035 2007-05-11

Related Child Applications (1)

Application Number Title Priority Date Filing Date
US12/503,598 Continuation US8110602B2 (en) 2007-01-16 2009-07-15 Compounds comprising heterocyclic-substituted piperidine for treating pain

Publications (2)

Publication Number Publication Date
WO2008089201A2 WO2008089201A2 (fr) 2008-07-24
WO2008089201A3 true WO2008089201A3 (fr) 2008-12-18

Family

ID=39434287

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2008/051096 Ceased WO2008089201A2 (fr) 2007-01-16 2008-01-15 Composés de pipéridine substituée hétérocycliques et leurs utilisations

Country Status (22)

Country Link
US (2) US8110602B2 (fr)
EP (3) EP2397477B1 (fr)
JP (2) JP5462633B2 (fr)
KR (2) KR101370434B1 (fr)
CN (1) CN101595100B (fr)
AT (1) ATE482206T1 (fr)
AU (2) AU2008206317B2 (fr)
CA (1) CA2675419C (fr)
CY (1) CY1111085T1 (fr)
DE (1) DE602008002690D1 (fr)
DK (1) DK2076506T3 (fr)
ES (1) ES2353448T3 (fr)
HR (1) HRP20100691T1 (fr)
IL (1) IL199741A0 (fr)
MX (1) MX2009007644A (fr)
NZ (2) NZ578078A (fr)
PL (1) PL2076506T3 (fr)
PT (1) PT2076506E (fr)
RS (1) RS51474B (fr)
SI (1) SI2076506T1 (fr)
WO (1) WO2008089201A2 (fr)
ZA (1) ZA200903742B (fr)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8846929B2 (en) 2007-08-31 2014-09-30 Purdue Pharma L.P. Substituted-quinoxaline-type piperidine compounds and the uses thereof

Families Citing this family (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2675419C (fr) 2007-01-16 2013-11-12 Purdue Pharma L.P. Composes de piperidine substituee heterocycliques et leurs utilisations
BRPI0911031B8 (pt) 2008-07-21 2021-05-25 Purdue Pharma Lp compostos de piperidina ligada do tipo quinoxalina substituídos e os usos destes
EP2394997A4 (fr) * 2009-02-03 2012-07-18 Mitsubishi Tanabe Pharma Corp Procédé de préparation de dérivés de 1-(4-pipéridinyl)benzimidazolone
CN102498108A (zh) 2009-09-08 2012-06-13 杏林制药株式会社 4-(5-甲基吡啶-2-基氨基)哌啶-1-甲酸衍生物的制造方法
KR101890442B1 (ko) * 2010-07-29 2018-08-21 닛뽕 케미파 가부시키가이샤 Ｐ2ｘ4 수용체 길항제
US9598447B2 (en) 2010-12-22 2017-03-21 Purdue Pharma L.P. Phosphorus-substituted quinoxaline-type piperidine compounds and uses thereof
EP2567959B1 (fr) 2011-09-12 2014-04-16 Sanofi Dérivés d'amide d'acide 6-(4-hydroxy-phényl)-3-styryl-1h-pyrazolo[3,4-b]pyridine-4-carboxylique en tant qu'inhibiteurs de kinase
WO2013080036A1 (fr) 2011-12-01 2013-06-06 Purdue Pharma L.P. Composés de pipéridine de type quinoxaline substituée par une azétidine et leurs utilisations
US9085561B2 (en) 2012-07-30 2015-07-21 Purdue Pharma L.P. Cyclic urea- or lactam-substituted quinoxaline-type piperidines as ORL-1 modulators
US9963458B2 (en) 2012-12-27 2018-05-08 Purdue Pharma L.P. Indole and indoline-type piperidine compounds and uses thereof
US10118927B2 (en) 2012-12-27 2018-11-06 Purdue Pharma L.P. Substituted piperidin-4-amino-type compounds and uses thereof
WO2014102594A2 (fr) 2012-12-27 2014-07-03 Purdue Pharma L.P. Composés de pipéridine de type benzimidazole substitué et leurs utilisations
US11767320B2 (en) 2020-10-02 2023-09-26 Incyte Corporation Bicyclic dione compounds as inhibitors of KRAS
EP4249489A4 (fr) * 2020-11-26 2023-10-18 Lg Chem, Ltd. Composé hétérocyclique en tant qu'inhibiteur de la diacylglycérol kinase et son utilisation
KR20240022630A (ko) * 2021-07-14 2024-02-20 이창 휴먼웰 파마슈티칼 코포레이션, 리미티드 피페리딘 유도체 및 그 약물 조성물, 제조 방법과 용도
WO2023229380A1 (fr) * 2022-05-25 2023-11-30 주식회사 엘지화학 Composé hétérocyclique en tant qu'inhibiteur de diacylglycérol kinase et son utilisation
KR20230164601A (ko) * 2022-05-25 2023-12-04 주식회사 엘지화학 다이아실글리세롤 키나아제 저해제로서 헤테로사이클 화합물 및 이의 용도

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2000006545A1 (fr) * 1998-07-27 2000-02-10 Schering Corporation Ligands d'affinite elevee pour recepteur de la nociceptine orl-1
WO2002085361A1 (fr) * 2001-04-18 2002-10-31 Euro-Celtique, S.A. Composes de benzimidazolone

Family Cites Families (43)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3536809A (en) 1969-02-17 1970-10-27 Alza Corp Medication method
US3598123A (en) 1969-04-01 1971-08-10 Alza Corp Bandage for administering drugs
US3845770A (en) 1972-06-05 1974-11-05 Alza Corp Osmatic dispensing device for releasing beneficial agent
US3916899A (en) 1973-04-25 1975-11-04 Alza Corp Osmotic dispensing device with maximum and minimum sizes for the passageway
US4008719A (en) 1976-02-02 1977-02-22 Alza Corporation Osmotic system having laminar arrangement for programming delivery of active agent
IE58110B1 (en) 1984-10-30 1993-07-14 Elan Corp Plc Controlled release powder and process for its preparation
US5073543A (en) 1988-07-21 1991-12-17 G. D. Searle & Co. Controlled release formulations of trophic factors in ganglioside-lipsome vehicle
IT1229203B (it) 1989-03-22 1991-07-25 Bioresearch Spa Impiego di acido 5 metiltetraidrofolico, di acido 5 formiltetraidrofolico e dei loro sali farmaceuticamente accettabili per la preparazione di composizioni farmaceutiche in forma a rilascio controllato attive nella terapia dei disturbi mentali organici e composizioni farmaceutiche relative.
US5120548A (en) 1989-11-07 1992-06-09 Merck & Co., Inc. Swelling modulated polymeric drug delivery device
US5733566A (en) 1990-05-15 1998-03-31 Alkermes Controlled Therapeutics Inc. Ii Controlled release of antiparasitic agents in animals
AU656154B2 (en) 1990-11-06 1995-01-27 Astellas Pharma Inc. Fused pyrazine derivative
US5698155A (en) 1991-05-31 1997-12-16 Gs Technologies, Inc. Method for the manufacture of pharmaceutical cellulose capsules
US5580578A (en) 1992-01-27 1996-12-03 Euro-Celtique, S.A. Controlled release formulations coated with aqueous dispersions of acrylic polymers
US5591767A (en) 1993-01-25 1997-01-07 Pharmetrix Corporation Liquid reservoir transdermal patch for the administration of ketorolac
GB9314977D0 (en) 1993-07-20 1993-09-01 Glaxo Spa Chemical compounds
US5739129A (en) 1994-04-14 1998-04-14 Glaxo Wellcome Inc. CCK or gastrin modulating 5-heterocyclic-1, 5 benzodiazepines
PE27497A1 (es) 1994-04-15 1997-08-07 Glaxo Inc Derivados de 1,5 benzodiazepina
IT1270594B (it) 1994-07-07 1997-05-07 Recordati Chem Pharm Composizione farmaceutica a rilascio controllato di moguisteina in sospensione liquida
SK79797A3 (en) 1994-12-23 1997-11-05 Thomae Gmbh Dr K Piperazine derivatives, medicaments containing the same, their use and process for preparing the same
JP3845876B2 (ja) 1995-04-20 2006-11-15 アステラス製薬株式会社 ピラジン誘導体又はその塩を含有する安定な注射用組成物及びその製造方法
CA2224517A1 (fr) 1995-06-12 1996-12-27 G.D. Searle & Co. Compositions comprenant un inhibiteur de cyclooxygenase-2 et un inhibiteur de 5-lipoxygenase
EP0990653B1 (fr) * 1997-05-30 2004-09-15 Banyu Pharmaceutical Co., Ltd. Derives de 2-0xoimidazole
US6030130A (en) * 1997-07-07 2000-02-29 George Paddock Ii, Inc. Body mounted camera support system
JP3342478B2 (ja) * 1998-01-19 2002-11-11 ファイザー製薬株式会社 Ｏｒｌ１−レセプターアゴニストとしての４−（２−ケト−１−ベンズイミダゾリニル）ピペリジン化合物
ES2356886T3 (es) 1998-03-31 2011-04-14 Kyowa Hakko Kirin Co., Ltd. Compuestos heterocíclicos nitrogenados.
US6262066B1 (en) * 1998-07-27 2001-07-17 Schering Corporation High affinity ligands for nociceptin receptor ORL-1
MA26659A1 (fr) 1998-08-06 2004-12-20 Pfizer Dérivés de benzimidazole nouveaux, compositions pharmaceutiques les contenant et procédé pour leur préparation.
WO2000023428A1 (fr) 1998-10-20 2000-04-27 Takeda Chemical Industries, Ltd. Composes de 1,5-benzodiazepine, procede de production de ces composes, et medicament
WO2001034571A1 (fr) 1999-11-09 2001-05-17 Eli Lilly And Company COMPOSES CONTENANT DES β-ACIDES AMINES UTILES POUR INHIBER LA LIBERATION ET/OU LA SYNTHESE DU PEPTIDE β-AMYLOIDE
US7456198B2 (en) * 1999-12-06 2008-11-25 Purdue Pharma L.P. Benzimidazole compounds having nociceptin receptor affinity
DE10013318A1 (de) 2000-03-17 2001-09-20 Merck Patent Gmbh Formulierung enthaltend Chinoxalinderivate
US6576644B2 (en) 2000-09-06 2003-06-10 Bristol-Myers Squibb Co. Quinoline inhibitors of cGMP phosphodiesterase
WO2002080895A2 (fr) 2001-04-06 2002-10-17 Schering Corporation Traitements antipaludiques comprenant l'administration d'inhibiteurs de la fasnesyl proteine transferase
UA74439C2 (uk) 2001-04-18 2005-12-15 Еро-Селтік, С.А. Сполуки спіропіразолу
MXPA03009602A (es) * 2001-04-18 2004-04-02 Euro Celtique Sa Analogos de nociceptina.
ES2323876T3 (es) * 2001-04-18 2009-07-27 Euro-Celtique S.A. Derivados de 1-(4-piperidinil)-1,3-dihidro-2h-benzoxazol-2-ona y compuestos relacionados como analogos de la nociceptina y ligandos de orl1 para el tratamiento del dolor.
US20030134846A1 (en) 2001-10-09 2003-07-17 Schering Corporation Treatment of trypanosoma brucei with farnesyl protein transferase inhibitors
US7001901B2 (en) 2002-08-27 2006-02-21 Bristol-Myers Squibb Company Tetrazolylpropionamides as inhibitors of Aβ protein production
US7067658B2 (en) 2002-09-30 2006-06-27 Bristol-Myers Squibb Company Pyridino and pyrimidino pyrazinones
UA80767C2 (en) 2002-12-20 2007-10-25 Pfizer Prod Inc Pyrimidine derivatives for the treatment of abnormal cell growth
CA2555219A1 (fr) 2004-02-03 2005-08-18 R. Richard Goehring Synthese de cyanoimino-benzoimidazoles
JP2008513368A (ja) 2004-09-15 2008-05-01 シェーリング−プラウ・リミテッド 置換８−アザビシクロ［３．２．１］オクタン−３−オールを調製する方法
CA2675419C (fr) 2007-01-16 2013-11-12 Purdue Pharma L.P. Composes de piperidine substituee heterocycliques et leurs utilisations

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2000006545A1 (fr) * 1998-07-27 2000-02-10 Schering Corporation Ligands d'affinite elevee pour recepteur de la nociceptine orl-1
WO2002085361A1 (fr) * 2001-04-18 2002-10-31 Euro-Celtique, S.A. Composes de benzimidazolone

Non-Patent Citations (3)

* Cited by examiner, † Cited by third party
Title
BIGNAN ET AL.: "Recent advances towards the discovery of ORL-1 receptor agonists and antagonists", EXP. OPIN. THER. PATENTS, vol. 15, no. 4, 1 January 2005 (2005-01-01), pages 357 - 388, XP002393017, ISSN: 1354-3776 *
POULAIN ET AL.: "From hit to lead. Analyzing Structure-profile relationships", J. MED. CHEM., vol. 44, 11 September 2001 (2001-09-11), pages 3391 - 3401, XP002395856, ISSN: 0022-2623 *
RONZONI ET AL.: "LEAD GENERATION AND LEAD OPTIMISATION APPROACHES IN THE DISCOVERY OF SELECTIVE, NON-PEPTIDE ORL-1 RECEPTOR AGONISTS AND ANTAGONISTS", EXPERT OPINION ON THERAPEUTIC PATENTS, INFORMA HEALTHCARE, GB, vol. 11, no. 4, 1 January 2001 (2001-01-01), pages 525 - 546, XP001146772, ISSN: 1354-3776 *

Cited By (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8846929B2 (en) 2007-08-31 2014-09-30 Purdue Pharma L.P. Substituted-quinoxaline-type piperidine compounds and the uses thereof
US9278967B2 (en) 2007-08-31 2016-03-08 Purdue Pharma L.P. Substituted-quinoxaline-type piperidine compounds and the uses thereof
US9527840B2 (en) 2007-08-31 2016-12-27 Purdue Pharma L.P. Substituted-quinoxaline-type piperidine compounds and the uses thereof

Also Published As

Publication number Publication date
EP2280008A2 (fr) 2011-02-02
CA2675419C (fr) 2013-11-12
AU2008206317A1 (en) 2008-07-24
US8637502B2 (en) 2014-01-28
KR20120051759A (ko) 2012-05-22
US20100022519A1 (en) 2010-01-28
NZ601683A (en) 2012-11-30
EP2397477A1 (fr) 2011-12-21
RS51474B (sr) 2011-04-30
MX2009007644A (es) 2009-07-27
HK1152296A1 (en) 2012-02-24
CN101595100B (zh) 2014-06-11
ES2353448T3 (es) 2011-03-02
DK2076506T3 (da) 2011-01-10
CN101595100A (zh) 2009-12-02
EP2076506A2 (fr) 2009-07-08
US20120108575A1 (en) 2012-05-03
CA2675419A1 (fr) 2008-07-24
AU2011200692A1 (en) 2011-03-10
SI2076506T1 (sl) 2011-01-31
EP2397477B1 (fr) 2014-03-05
KR101227072B1 (ko) 2013-01-29
KR20090101314A (ko) 2009-09-24
IL199741A0 (en) 2010-04-15
HRP20100691T1 (hr) 2011-01-31
EP2280008A3 (fr) 2011-07-06
AU2008206317B2 (en) 2012-02-02
DE602008002690D1 (de) 2010-11-04
EP2280008B1 (fr) 2013-05-29
ATE482206T1 (de) 2010-10-15
KR101370434B1 (ko) 2014-03-06
PL2076506T3 (pl) 2011-03-31
ZA200903742B (en) 2010-02-24
EP2076506B1 (fr) 2010-09-22
PT2076506E (pt) 2010-12-10
WO2008089201A2 (fr) 2008-07-24
NZ578078A (en) 2011-11-25
US8110602B2 (en) 2012-02-07
AU2011200692B2 (en) 2012-02-09
JP2010516687A (ja) 2010-05-20
JP2014040467A (ja) 2014-03-06
CY1111085T1 (el) 2015-06-11
JP5462633B2 (ja) 2014-04-02

Similar Documents

Publication Publication Date Title
WO2008089201A3 (fr) Composés de pipéridine substituée hétérocycliques et leurs utilisations
WO2009027820A3 (fr) Composés de pipéridine de type quinoxaline substituée et leurs utilisations
MY153948A (en) Substituted-quinoxaline-type bridged-piperidine compounds and the uses thereof
WO2008132600A3 (fr) Antagonistes de trpv1 et utilisations de ceux-ci
WO2009147205A3 (fr) Mélanges fongicides synergiques
WO2008148074A3 (fr) Inhibiteurs de mtor et methodes de traitement mettant en œuvre ces inhibiteurs
WO2007139967A3 (fr) Composés de triazole modulant l&#39;activité de hsp90
WO2007139955A3 (fr) Composés de triazole qui modulent l&#39;activité de la hsp90
WO2007139968A3 (fr) Composés de triazole qui modulent l&#39;activité de la hsp90
WO2012024620A3 (fr) Inhibiteurs de l&#39;autotaxine et leurs utilisations
MX2009000285A (es) Piperidinas sustituidas que incrementan la actividad de p53 y usos de las mismas.
WO2007133637A3 (fr) Dérivés d&#39;amides en tant que ligands de canal ionique et compositions pharmaceutiques et méthodes d&#39;utilisation desdits dérivés
WO2010069763A3 (fr) Mélanges fongicides synergiques
WO2007139960A3 (fr) Composés modulant l&#39;activité de hsp90 et méthodes d&#39;identification de ces composés
WO2009059048A3 (fr) Opioïdes-(+) et méthodes d&#39;utilisation
WO2007109182A3 (fr) Composés de bicyclohétéroaryle en tant que modulateurs de p2x7 et leurs utilisations
WO2007109201A3 (fr) Composés de bicyclohétéroaryle en tant que modulateur de p2x7 et leurs utilisations
WO2009000843A3 (fr) Traitement de l&#39;insuffisance cardiaque chez les animaux mammifères non humains par un antagoniste de l&#39;aldostérone
WO2008112647A3 (fr) Radical nitroxyde en tant que traitement pour la neurodégénération
WO2010106008A3 (fr) Compositions fongicides comprenant du fluopyram et de la métrafénone
WO2014020405A8 (fr) Composés de pipéridine cycliques de type quinoxaline substitués par un groupe dérivé d&#39;urée ou un groupe dérivé de lactame et leurs utilisations
WO2009011910A3 (fr) Composés d&#39;imidazolidinone, procédés pour inhiber une désubiquitination et procédés de traitement
WO2011011706A3 (fr) Méthodes et compositions pour le traitement ou la prévention de maladies auto-immunes utilisant des agents immunomodulateurs
WO2006131874A3 (fr) Procedes de traitement ou de prophylaxie de l&#39;atherosclerose et d&#39;une lesion de reperfusion
WO2010045212A3 (fr) Ligands des récepteurs cholinergiques nicotiniques et leurs utilisations

Legal Events

Date Code Title Description
WWE Wipo information: entry into national phase

Ref document number: 200880002219.8

Country of ref document: CN

121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 08727696

Country of ref document: EP

Kind code of ref document: A2

WWE Wipo information: entry into national phase

Ref document number: 2008727696

Country of ref document: EP

WWE Wipo information: entry into national phase

Ref document number: 3827/DELNP/2009

Country of ref document: IN

WWE Wipo information: entry into national phase

Ref document number: 578078

Country of ref document: NZ

Ref document number: 2008206317

Country of ref document: AU

WWE Wipo information: entry into national phase

Ref document number: 199741

Country of ref document: IL

WWE Wipo information: entry into national phase

Ref document number: 2675419

Country of ref document: CA

ENP Entry into the national phase

Ref document number: 2009546482

Country of ref document: JP

Kind code of ref document: A

WWE Wipo information: entry into national phase

Ref document number: MX/A/2009/007644

Country of ref document: MX

NENP Non-entry into the national phase

Ref country code: DE

ENP Entry into the national phase

Ref document number: 2008206317

Country of ref document: AU

Date of ref document: 20080115

Kind code of ref document: A

WWE Wipo information: entry into national phase

Ref document number: 1020097017069

Country of ref document: KR

WWE Wipo information: entry into national phase

Ref document number: P-2010/0489

Country of ref document: RS

WWE Wipo information: entry into national phase

Ref document number: 1020127008578

Country of ref document: KR